A B S T R A C T These studies were undertaken to examine whether an antagonism between vasopressin and prostaglandin occurs in vivo in the mammalian kidney. All experiments were performed in steroid-replaced hypophysectomized dogs undergoing a water diuresis. In the first group of studies the effect of two consecutive intravenous doses (100 mU) of vasopressin was examined. The second dose of vasopressin was preceded by an injection of the carrier solution for solubilizing indomethacin or meclofenamate. No enhancement of the antidiuretic effect of the second dose of vasopressin was observed as urinary osmolality (Uosm) increased from 92±5 to 252±+18 mosmol/kg H2O (P < 0.001) after the first dose and from 109±8 to 209±+10 mosmol/kg HaO (P < 0.001) after the second dose of vasopressin. In another group of studies the second dose of vasopressin was preceded by the administration of a potent inhibitor of prostaglandin synthesis, indomethacin (2 mg/kg). The Uosm increased from 93±9 to 244±33 mosmol/kg H2O (P < 0.001) after the first dose of vasopressin, but after the second dose of vasopressin the Uosm increased to a significantly greater degree from 106±14 to 702+69 mosmol/kg H20 (P < 0.001).
A B S T R A C T These studies were undertaken to examine whether an antagonism between vasopressin and prostaglandin occurs in vivo in the mammalian kidney. All experiments were performed in steroid-replaced hypophysectomized dogs undergoing a water diuresis. In the first group of studies the effect of two consecutive intravenous doses (100 mU) of vasopressin was examined. The second dose of vasopressin was preceded by an injection of the carrier solution for solubilizing indomethacin or meclofenamate. No enhancement of the antidiuretic effect of the second dose of vasopressin was observed as urinary osmolality (Uosm) increased from 92±5 to 252±+18 mosmol/kg H2O (P < 0.001) after the first dose and from 109±8 to 209±+10 mosmol/kg HaO (P < 0.001) after the second dose of vasopressin. In another group of studies the second dose of vasopressin was preceded by the administration of a potent inhibitor of prostaglandin synthesis, indomethacin (2 mg/kg). The Uosm increased from 93±9 to 244±33 mosmol/kg H2O (P < 0.001) after the first dose of vasopressin, but after the second dose of vasopressin the Uosm increased to a significantly greater degree from 106±14 to 702+69 mosmol/kg H20 (P < 0.001).
In a third group of studies the antidiuretic effect of the same 100-mU dose of vasopressin was examined before and after the administration of meclofenamate (2 mg/ kg), an inhibitor of prostaglandin synthesis which is chemically dissimilar from indomethacin. Uosm increased from 83±7 to 216±16 mosmol/kg H20 (P < 0.001) after the first dose and from 101±8 to 734+86 mosmol/kg Ha0 (P <0.001) after the second dose of vasopressin. As (20, 21) . Furthermore, prostaglandins have been demonstrated to inhibit vasopressin-mediated increases in cyclic AMP production in toad bladder epithelium (22) and rat renal medulla (23) , as well as vasopressinmediated increases in adenyl cyclase activity in hamster renal medulla (24) . These latter findings (22) (23) (24) suggest an explanation for the mechanism whereby prostaglandin E1 may antagonize the effect of vasopressin on osmotic water movement. [15] [16] [17] [18] [19] [20] mg/100 ml and 1-3 mg/100 ml, respectively. Throughout the remainder of the experiment, 2.5 g/100 ml dextrose was infused at a rate of 2-4 ml/min above urine flow rate. The periods of urine collection during the experiments were 5-10 min in duration and arterial and renal venous blood samples were obtained at the midpoint of alternate urine collections. The experimental protocol for the experiments is demonstrated in Fig. 1 . After an equilibration period to allow for recovery from surgery and stabilization of urine flow, urine samples for precontrol clearance measurements were collected. Immediately after these collections, an intravenous bolus of 100 mU vasopressin (aqueous Pitressin, Parke, Davis & Company, Detroit, Mich.) was administered. After a 10-min equilibration period, experimental clearance periods were obtained. After the effect of vasopressin on urine flow had disappeared, approximately 45 min after its administration, postcontrol urine collections were made. After these collections, the animals randomly received an intravenous bolus of one of three solutions: six dogs were given indomethacin, 2 mg/kg; seven dogs received meclofenamate, 2 mg/kg; and seven dogs were given a control solution consisting only of the carrier solutions used for solubilizing indomethacin or meclofenamate. In two of the indomethacin studies, one of the kidneys was not used because of surgical mishap. 10 min after the injection of one of the three solutions, precontrol periods were obtained again and were followed immediately by a second intravenous bolus of 100 mU vasopressin. As before, clearance measurements were started within 10 min and postcontrol clearance measurements were obtained later after the effects of vasopressin (27) . Student's t test and analysis of variance were used for statistical analysis. A P value < 0.05 was considered significant.
RESULTS
The effect of vasopressin on urinary osmolality in seven control animals receiving a carrier solution before the second dose of vasopressin is shown in Fig. 2 . Urine osmolality (Uosm)' rose from 92±5 to 252±18 mosmol/ kg H20 (P < 0.001) and fell to 114±7 mosmol/kg H20 (P < 0.001) after the first injection of vasopressin. With the second dose of vasopressin Uosm increased from 109±8 to 209+10 mosmol/kg H20 (P < 0.001) and fell to 112±9 mosmol/kg H20 (P <0.001) in the postcontrol period. The magnitude of the antidiuresis was slightly but significantly less after the second dose of vasopressin (P < 0.005). Free water clearance (CtH20) demonstrated parallel changes in these control animals. With the first injection of vasopressin CH2O declined from 1.54±0.32 to 0.23±0.13 ml/min (P < 0.001) and returned to 1.39±0.21 ml/min in the post control period (P <0.001). CH2o declined from 1.65+ 0.19 to 0.43±0.11 ml/min (P < 0.001) with the second injection of vasopressin and rose to 1.73±0.27 ml/min in the postcontrol period (P < 0.001). Although the decrease in CH20 was less after the second injection of vasopressin, this difference was not statistically significant.
The effect of vasopressin on Uosm in six animals treated before the second dose of vasopressin with indomethacin (2 mg/kg) is shown in Fig. 3 in Cn2o after indomethacin were significantly greater (P <0.05) than that observed in the control animals after an injection of carrier solution.
Further studies were undertaken with meclofenamate, a chemically dissimilar inhibitor of prostaglandin synthetase (26, 28) . The results of sequential doses of vasopressin on Uosm in seven animals treated with meclofenamate (2 mg/kg) before the second dose of vasopressin are shown in Fig. 4 . The response to the first dose of vasopressin was similar to that observed in the control and indomethacin-treated animals as Uosm increased from 83±7 to 216±+16 mosmol/kg H20 (P < 0.001) and fell to 102±7 mosmol/kg H20 (P < 0.001).
In contrast to the control animals, but similar to the animals that received indomethacin, the response to vasopressin was enhanced after meclofenamate as Uosm rose from 101±8 to 734±86 mosmol/kg H20 (P < 0.001) and fell to 118±12 mosmol/kg H20 (P < 0.001).
This increase in Uosm after vasopressin in these meclofenamate-treated dogs was significantly greater than that observed in control animals (P < 0.001). Changes in CH20 with the first injection of vasopressin in these animals were similar to those observed in both the control and indomethacin groups, as CH2o decreased from 1.82±0.28 to 0.26±0.09 ml/min (P <0.001) and rose to 1.36±0.20 (P <0.001) in the postcontrol period. In contrast to the control animals and similar to the indomethacin-treated animals, the second injection of vasopressin resulted in a greater fall in CH920 from 1.47± 0.05 to -0.58±0.06 ml/min (P <0.001), which rose to 1.46±0.23 ml/min (P < 0.001) in the postcontrol period. This effect on CH2o was also significantly greater than in the control animals (P < 0.05). The glomerular filtration rate, renal blood flow, and solute excretion for all of -the studies are shown in Fig. 5 . No significant differences in these parameters for any experimental group was observed. DISCUSSION Several lines of evidence derived from in vitro experiments suggest that the prostaglandins inhibit the hydro-osmotic action of vasopressin (16) (17) (18) (19) . Attempts to evaluate the physiologic significance of these findings in vivo have been based on experiments in which exogenous prostaglandins were infused systemically (11) or into a renal artery (6, 7). Many difficulties have arisen in interpreting such experiments. First, when prostaglandins of the E or A series are given systemically they cause vasodilatation, a decrease in arterial pressure, and an increase in release of vasopressin (11) . These effects are likely to obscure any influence the prostaglandins might have on the renal hydro-osmotic action of vasopressin. Similarly, when the pros- taglandins are infused intrarenally they cause increased solute excretion and renal vasodilatation (6) . Both of these effects might interfere with the ability of vasopressin to enhance urine concentration without necessarily alteiing its cellular action on collecting ducts (29, 30) . Furthermore, exogenously infused prostaglandins are likely to be distributed within the kidney quite differently from endogenous renal prostaglandins. Endogenous prostaglandins occur in greater concentration in the medulla (14, 15), while prostaglandins infused into the renal artery may be distributed primarily to the cortex, which receives approximately 90% of renal blood flow. Since the medullary collecting ducts are the major site of action of vasopressin, renal prostaglandins in the medulla are well situated to play a modulating role on the tubular response to vasopressin. In the present study another approach was used in an effort to document an in vivo effect of endogenous prostaglandins on vasopressin activity. The renal responsiveness to exogenous vasopressin was evaluated before and after the administration of indomethacin, a drug known to inhibit the synthesis of endogenous prostaglandins (1, 26, 28, 31) . The main finding in our study was that the response of urinary osmolality to vasopressin was enhanced threefold by pretreatment with indomethacin. The enhancement occurred despite solute excretion rates, total renal blood flow, and estimated distal tubular fluid delivery rates which were no different to those existing before treatment with indomethacin. Several controls were integrated into the present study to insure that indomethacin was primarily responsible for the observed enhancement of vasopressin activity. First, the studies were performed in dogs that had been acutely hypophysectomized. Previous studies have shown that in such hypophysectomized animals vasopressin release in response to a wide variety of acute stimuli is virtually abolished (11, 25, (32) (33) (34) . Thus, any effects on urinary osmolality due to alterations in endogenous vasopressin were minimized. Moreover, both pre-and postcontrol periods were obtained after each bolus of exogenous vasopressin to exclude any residual effect of endogenous vasopressin.
Another control designed for the present study was the injection of two identical doses of vasopressin into the same dog before and after infusion of indomethacin. Thus, each dog served as its own control. In a series of control animals, which received no indomethacin, the variability of the response to two separate doses of vasopressin was also assessed. In the absence of indomethacin the response to the second dose of vasopressin was not statistically greater than the first. Therefore, the present results clearly demonstrate that indomethacin potentiates the action of vasopressin on the kidney.
The logical inference to be drawn from our results is that indomethacin enhances the action of vasopressin by blocking endogenous prostaglandin production. However, other hypotheses must also be considered. It is recognized that indomethacin exerts other effects in addition to the inhibition of prostaglandin synthetase. For example, the drug is capable of inhibiting cyclic nucleotide phosphodiesterase (18, 35) . However, this action only occurs at concentrations approximately 100-fold greater than those required to inhibit prostaglandin synthetase (35) . In our in vivo experiments the concentration of indomethacin was much less than would be expected to induce significant inhibition of phosphodiesterase. Moreover, the in vitro effect of indomethacin to enhance the hydro-osmotic effect of vasopressin occurs when phosphodiesterase activity is inhibited by theophylline (18) .
Even so, it was apparent that an attempt to duplicate the enhancement of vasopressin activity with a chemically dissimilar inhibitor of prostaglandin synthetase was necessary. Studies, therefore, were performed with the same experimental protocol, except that meclofenamate rather than indomethacin was used as the inhibitor of prostaglandin synthesis. The results showed that meclofenamate was almost identical to indomethacin in its ability to enhance vasopressin activity. Since the only known action shared by indomethacin and meclofenamate is inhibition of prostaglandin synthesis (36) , the inference can logically be drawn that it is through this common action that these agents potentiate the action of vasopressin.
Taken together, therefore, the present results indicate that endogenous prostaglandins are important in vivo modulators of the kidney's response to vasopressin.
This conclusion is in agreement with in vitro studies in the toad bladder (16) (17) (18) and rabbit collecting duct (19) which have demonstrated that prostaglandin E1 antagonizes the hydro-osmotic effect of vasopressin. Further evidence is the finding in the toad bladder that indomethacin enhances the hydro-osmotic effect of vasopressin (20, 21) . Vasopressin-mediated increases in cyclic AMP also have been found to be inhibited by prostaglandin in toad bladder epithelium (22) and rat renal medulla (23) , and prostaglandin also inhibits vasopressin-stimulated increases in adenyl cyclase activity in the hamster renal medulla (24) . 
